NasdaqGS - Nasdaq Real Time Price • USD
Moderna, Inc. (MRNA)
As of 12:11 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 21 | 21 |
| Avg. Estimate | -3.1 | -0.98 | -6.56 | -4.84 |
| Low Estimate | -3.87 | -2.97 | -7.85 | -6.63 |
| High Estimate | -2.67 | -0.16 | -5.58 | -0.91 |
| Year Ago EPS | -3.62 | -9.53 | -12.33 | -6.56 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 22 | 21 |
| Avg. Estimate | 125.18M | 1.42B | 3.83B | 4.36B |
| Low Estimate | 71.84M | 379.73M | 3.31B | 3.29B |
| High Estimate | 211.83M | 1.83B | 4.29B | 5.41B |
| Year Ago Sales | 344M | 1.83B | 6.85B | 3.83B |
| Sales Growth (year/est) | -63.60% | -22.30% | -44.10% | 13.90% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -4.04 | -1.93 | -0.97 | -3.3 |
| EPS Actual | -3.62 | -9.53 | 0.55 | -2.83 |
| Difference | 0.42 | -7.6 | 1.52 | 0.47 |
| Surprise % | 10.40% | -393.80% | 156.70% | 14.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -3.1 | -0.98 | -6.56 | -4.84 |
| 7 Days Ago | -3.36 | -1.09 | -7.14 | -5.28 |
| 30 Days Ago | -3.23 | -1.02 | -6.81 | -4.99 |
| 60 Days Ago | -3.5 | -1 | -7.2 | -5.19 |
| 90 Days Ago | -3.32 | -1.08 | -7.1 | -4.97 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 3 | 3 | 2 |
| Up Last 30 Days | 4 | 3 | 3 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | MRNA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 14.40% | -- | -- | 8.90% |
| Next Qtr. | 89.70% | -- | -- | 11.40% |
| Current Year | 46.80% | -- | -- | 5.80% |
| Next Year | 26.20% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -47.28% | -- | -- | 11.45% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Hold | 6/3/2024 |
| Initiated | Evercore ISI Group: In-Line | 5/14/2024 |
| Maintains | UBS: Buy to Buy | 5/7/2024 |
| Maintains | Canaccord Genuity: Hold to Hold | 5/3/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 5/3/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 5/3/2024 |
Related Tickers
NVAX Novavax, Inc.
17.95
+19.40%
BNTX BioNTech SE
102.59
+1.97%
INSM Insmed Incorporated
57.74
+4.89%
NVO Novo Nordisk A/S
135.87
+0.43%
SMMT Summit Therapeutics Inc.
9.48
+9.08%
VKTX Viking Therapeutics, Inc.
61.55
-1.14%
CRSP CRISPR Therapeutics AG
57.11
+6.26%
VRTX Vertex Pharmaceuticals Incorporated
467.26
+2.62%
SRPT Sarepta Therapeutics, Inc.
123.72
-4.73%
RXRX Recursion Pharmaceuticals, Inc.
8.54
+3.08%